HSP90抑制剂RGRN-305口服治疗斑块型银屑病:一项开放标签概念验证研究的疗效、安全性和生物标志物结果
这项开放标签、单臂、剂量选择、单中心概念验证研究评估了HSP90抑制剂RGRN-305治疗斑块型银屑病的安全性和疗效。11例完成研究的患者中6例PASI改善71%至94%,5例无应答(PASI应答<50%)。未报告严重不良事件,500mg组7例中4例出现轻度至中度药物性发疹。
要点
- 11例完成研究患者中6例对RGRN-305应答,PASI改善71%至94%。
- 5例无应答者PASI应答<50%。
- 未报告严重不良事件;500mg组7例中4例出现轻度至中度药物性发疹。
核心结论
- RGRN-305治疗显示可接受的安全性,尤其在低剂量组,并与部分斑块型银屑病患者的临床有意义改善相关,提示HSP90可能作为银屑病治疗的新靶点。
研究设计与样本
- 开放标签、单臂、剂量选择、单中心概念验证研究。
- 斑块型银屑病患者每日接受250 mg或500 mg RGRN-305治疗12周。
- 疗效通过PASI、BSA、PGA评分和DLQI临床评估。
- 基线及治疗开始后4、8、12周采集皮肤活检用于免疫组化染色和基因表达分析。
- 安全性通过实验室检查、生命体征、心电图和体格检查监测。
主要发现
- 11例完成研究患者中6例对RGRN-305应答,PASI改善71%至94%。
- 5例患者被认为无应答,PASI应答<50%。
- 未报告严重不良事件。
- 每日500 mg RGRN-305治疗的7例患者中4例出现因研究治疗导致的轻度至中度药物性发疹。
- 2例患者因该发疹选择退出研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HSP90 is a downstream regulator of tumour necrosis factor (TNF)-α and interleukin (IL)-17A signalling and may therefore serve as a novel target in the treatment of psoriasis. OBJECTIVES: This phase Ib proof-of-concept study was undertaken to evaluate the safety and efficacy of a novel HSP90 inhibitor (RGRN-305) in the treatment of plaque psoriasis. METHODS: We conducted an open-label, single-arm, dose-selection, single-centre proof-of-concept study. Patients with plaque psoriasis were treated with 250 mg or 500 mg RGRN-305 daily for 12 weeks. Efficacy was evaluated clinically using the Psoriasis Area and Severity Index (PASI), body surface area (BSA), Physician's Global Assessment (PGA) scores and the Dermatology Life Quality Index (DLQI). Skin biopsies collected at baseline and at 4, 8 and 12 weeks after initiation of treatment were used for immunohistochemical staining and for gene expression analysis. Safety was monitored via laboratory tests, vital signs, electrocardiogram and physical examinations. RESULTS: Six of the 11 patients who completed the study responded to RGRN-305 with a PASI improvement between 71% and 94%, whereas five patients were considered nonresponders with a PASI response < 50%. No severe adverse events were reported. Four of seven patients treated with 500 mg RGRN-305 daily experienced a mild-to-moderate exanthematous drug-induced eruption owing to the study treatment. Two patients chose to discontinue the study because of this exanthematous eruption. RGRN-305 treatment resulted in pronounced inhibition of the IL-23, TNF-α and IL-17A signalling pathways and normalization of both histological changes and psoriatic lesion gene expression profiles in patients who responded to treatment. CONCLUSIONS: Treatment with RGRN-305 showed acceptable safety, especially in the low-dose group, and was associated with clinically meaningful improvement in a subset of patients with plaque psoriasis, indicating that HSP90 may serve as a novel future target in psoriasis treatment.
引用
- Bregnhøj A, Thuesen KKH, Emmanuel T, et al. HSP90 inhibitor RGRN-305 for oral treatment of plaque-type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study. Br J Dermatol. 2022. PMID: 34748646. doi:10.1111/bjd.20880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。